Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2020-05-06 Interim / Quarterly Rep…
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Information financière trimestrielle / Information financière du premier trimestre
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial update from Transgene (dated May 6, 2020) covering the first quarter of 2020. It provides specific financial data (operating income, cash position, cash burn) and a detailed status report on clinical trials and business activities. It is not a full annual report (10-K) nor a mere announcement of a report (RPA), as it contains substantive financial tables and operational analysis. Therefore, it is classified as an Interim/Quarterly Report (IR). Q1 2020
2020-05-06 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 1% confidence The document is titled "Mise à disposition des documents préparatoires à l'Assemblée générale du 27 mai 2020" (Making available of preparatory documents for the General Meeting of May 27, 2020). It explicitly states that the company has put online the preparatory documents for the mixed General Meeting (Ordinary and Extraordinary). It mentions the publication of the notice of meeting including the agenda and draft resolutions in the BALO. This content strongly indicates an announcement related to the upcoming Annual General Meeting (AGM) and the availability of related materials, rather than the AGM presentation itself or the voting results. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it is an announcement about the meeting documents, AGM-R covers materials shared during or prepared for the AGM, which fits better than RPA (Report Publication Announcement) which is usually for financial reports.
2020-04-03 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 3, 2020, from Transgene and BioInvent announcing that they will present preclinical data on their product BT-001 at several scientific congresses (ESMO TAT, IO Summit Europe, Keystone Symposium, AACR 2020). It also mentions the submission of an application for a first-in-human clinical trial. This type of announcement, detailing future scientific presentations and clinical trial progress updates, is characteristic of communications aimed at investors and the scientific community regarding ongoing research and development activities, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR, IR). Since it focuses on presenting data at conferences and updating on clinical trial progress, it aligns best with an Investor Presentation (IP) or a general announcement. Given the context of presenting data at scientific meetings, 'Investor Presentation' (IP) is a strong fit, as these announcements often precede or accompany investor-focused presentations. However, since this is an announcement *about* presentations and clinical progress, and not the presentation document itself, it functions as a general corporate update. If the document were purely about the *publication* of a report, RPA or RNS would apply. Since it details scientific progress and upcoming conference presentations, it is best classified as an Investor Presentation (IP) announcement or a general Regulatory Filing (RNS) if IP is too specific for an announcement. Given the focus on scientific data dissemination and clinical pipeline updates, IP is the most descriptive category for the *content* being discussed, even if the format is a press release. If we must choose from the list, and considering it's a detailed update on pipeline progress and scientific dissemination, IP is the closest fit for the nature of the information shared with investors, even if it's not the presentation file itself. Alternatively, RNS serves as a good catch-all for non-standard corporate news. Given the high level of detail about specific scientific congresses and clinical milestones, I will lean towards Investor Presentation (IP) as the intended classification for this type of pipeline update, recognizing it is an announcement *of* such information.
2020-03-03 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated March 3, 2020, announcing that Transgene and BioInvent will present preclinical data on their product BT-001 at several upcoming scientific congresses (ESMO TAT, IO Summit Europe, Keystone Symposium, and AACR 2020). It details the science, quotes management, and lists the presentation schedules. This type of announcement, focusing on scientific data presentation and upcoming clinical trial applications, is characteristic of an Investor Presentation (IP) or a general press release related to research updates. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR, IR), and it is clearly designed to inform investors and the public about scientific progress and upcoming events, 'Investor Presentation' (IP) is the most fitting category, although it functions as a press release detailing scientific milestones. Given the options, it is a communication aimed at investors about ongoing development, which aligns best with IP, rather than a general Regulatory Filing (RNS) or a specific financial report.
2020-03-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated February 20, 2020, announcing a significant operational milestone: the first patient treated in a new clinical trial (Phase 1/2a) for their drug candidate TG6002. It details the trial design, the mechanism of action of the drug, and includes quotes from the investigator and company management regarding the progress. This type of announcement, focusing on clinical trial updates, drug development progress, and operational news, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement of clinical progress rather than a comprehensive periodic financial report (like 10-K or IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's just a corporate update. Given the content is a detailed update on a clinical trial and operational progress, and it is not a formal financial statement, 'ER' (Earnings Release) is often used broadly for major operational updates, but 'RNS' (Regulatory Filings) is the safest general category for non-standard, material corporate news that isn't a specific financial report or management change. However, since it is a detailed announcement of clinical progress, which often accompanies or precedes earnings, and it is not a formal financial statement, I will classify it as a general Regulatory Filing (RNS) as it is a material corporate announcement that doesn't fit the other specific categories like MANG, DIV, or CAP. It is not a short announcement pointing to another document, so RPA is incorrect. It is not a management change (MANG) or a capital event (CAP). It is a material corporate update, making RNS the most appropriate fallback.
2020-02-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Transgene announcing that the first patient has been dosed in a clinical trial for their oncolytic virus TG6002. It details the trial design (Phase 1/2a), the treatment mechanism, and future reporting expectations (Q2 2020 data from another trial). This type of announcement, detailing clinical trial progress, scientific updates, and corporate news, is characteristic of an Earnings Release (ER) or a general press release. Since it is not a full financial report (10-K, IR), a specific regulatory filing (like DIRS, DVA), or a presentation (IP), and it focuses on operational/clinical progress, it best fits the 'Earnings Release' category, which often includes operational highlights and clinical milestones, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the content is a major operational update (first patient dosed) rather than just a notice of a report, ER is a strong candidate, but since it is not explicitly tied to quarterly financial results (though it mentions future Q2 data), the most appropriate general category for significant, non-standardized corporate news is often RNS, or ER if it's part of a regular reporting cycle. However, based on the provided definitions, this is a scientific/clinical update press release. Since there is no specific 'Clinical Trial Update' code, and it is not a formal financial report, it falls under the general announcement category. Given the context of financial reporting databases, major operational announcements like this are often grouped with Earnings Releases or Regulatory Filings. I will classify it as an Earnings Release (ER) as these often contain operational milestones alongside financial highlights, or RNS as a fallback. Given the focus is purely on clinical progress and not financial results, RNS (Regulatory Filings - general announcement) is the safest fit if ER implies financial results are the primary focus. Let's re-evaluate: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical trial update, not a financial result highlight. Therefore, RNS (General regulatory announcements and fallback) is the most appropriate category for a significant, non-financial press release.
2020-02-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.